Ternary Therapeutics

Investor: daphni

Ternary Therapeutics, a London-based biotech startup founded in 2024, has successfully closed a £3.6 million seed funding round. This investment will fuel the development of its innovative AI platform designed to systematically create 'molecular glues,' a novel class of medicines capable of targeting previously 'undruggable' proteins.Summary of transaction details:Value: £3.6 million seed investmentSector: Biotechnology, AI in Drug Discovery, Health TechAdvisor: None mentionedKey Entities:Target: Ternary TherapeuticsLead Investor: daphniOther Investors: Pace Ventures, i&i Biotech Fund, UK Innovation & Science Seed Fund (managed by Future Planet Capital)Location: London, UK (Target Company)Note: The strategic rationale behind this funding is to capitalize on the transformative potential of AI and machine learning to overcome the historical challenges in discovering molecular glues. By enabling intentional design rather than chance discovery, Ternary Therapeutics aims to accelerate the development of highly effective drugs for complex diseases, positioning itself at the forefront of precision medicine.

Investor: daphni

Ternary Therapeutics has secured £3.6 million in seed funding to accelerate the development of its artificial intelligence-driven platform for next-generation drugs. Summary of transaction details: Value: £3.6 million Sector: Healthcare & Biotech Advisor: None Key Entities: Ternary Therapeutics, daphni Location: London, UK Note: The investment reflects growing momentum across the biotechnology sector around targeted protein degradation, an approach that seeks to eliminate disease-causing proteins rather than simply blocking their activity.